Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of CTNM will rise by +4.45% over the next 2 Weeks and hit $16.02 by Monday, March 16, 2026. In that time frame, CTNM's share price is expected to range between $15.39 and $16.63.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Mar 16, 2026 | 15.39 | 16.02 | 16.63 |
| Mar 13, 2026 | 15.58 | 16.12 | 16.68 |
| Mar 12, 2026 | 15.78 | 16.33 | 16.91 |
| Mar 11, 2026 | 15.73 | 16.29 | 16.85 |
| Mar 10, 2026 | 15.62 | 16.21 | 16.76 |
| Mar 9, 2026 | 15.15 | 15.66 | 16.19 |
| Mar 6, 2026 | 15.19 | 15.76 | 16.24 |
| Mar 5, 2026 | 15.42 | 15.96 | 16.46 |
| Mar 4, 2026 | 15.40 | 15.92 | 16.44 |
| Mar 3, 2026 | 15.30 | 15.84 | 16.35 |
CTNM shares remained flat 0 in Monday, March 2, 2026's trading session, starting and closing at a previous close of $15.34 to move at $15.34. The stock demonstrated notable intraday movement (see CTNM's key stats for a full breakdown), fluctuating between $14.33 and $15.47, a +7.92% trading range. While recent weeks have seen some volatility, CTNM has managed to secure a +4.42% gain over the past 2 weeks. The neutral price movement was accompanied by increased trading volume, with approximately 220.43K shares changing hands, 7.08K more than the previous session. This amounted to $3.38M in total market activity.
Will CTNM Continue Its Upward Trend?
According to analyst ratings and projections for CTNM, Contineum Therapeutics, Inc. Class A Common Stock shares are anticipated to increase by +7.75%, potentially reaching $16.63 per share by March 16, 2026. Short-term technical indicators currently suggest a neutral sentiment for CTNM. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 17 positive trading days within the past 30 sessions. Based on the CTNM stock forecast, now is a good time to buy CTNM stock because its current trading price is -4.26% below our predicted value, hinting at a possible overvaluation. For deeper insights, view our sentiment analysis on CTNM covering social and institutional perspectives.
CTNM Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into CTNM's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 53.84% to 59.05%) suggest the stock is in a neutral to slightly bearish momentum phase. The 50-day RSI, at 58.00%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 55.69%, maintains a neutral outlook for the long term. Insights into CTNM's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Contineum Therapeutics Class A Common Stock Short-Term Forecasts
CTNM Forecast For Next 5 Days
Our algorithm anticipates Contineum Therapeutics Class A Common Stock (CTNM) stock could hit $13.20 by Mar 09, 2026. This represents a -13.96% rise from today's price, following a +29.23% change over the past five days.
CTNM Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $15.04, which would mean a -1.96% decrease from the current price of $15.34. Projections for this period range from a high of $18.20 to a low of $11.59.
CTNM Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Contineum Therapeutics Class A Common Stock's price over the next three months point to a drop. CTNM stock is expected to peak at $16.69 on Mar 19, 2026 before potentially dipping to $10.27 on Jun 02, 2026. On average, CTNM is likely to trade around $13.38 in the coming 90 days.
Contineum Therapeutics Class A Common Stock Stock Forecast 2025
Based on our predictive models, Contineum Therapeutics Class A Common Stock (CTNM) is expected to trade between $8.00 and $16.69 throughout 2026. This would result in an average price of $12.36, potentially offering investors a -19.43% return from current levels.
Contineum Therapeutics, Inc. Class A Common Stock Monthly Forecast 2026–2027
March 2026
According to our latest forecast models, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is positioned to show a strong performance in March 2026. The price is predicted to move between $12.13 and $16.69, settling at an average of $14.48. This could translate to a -5.61% loss.
April 2026
Based on current market signals, Contineum Therapeutics, Inc. Class A Common Stock is projected to trend april 2026. We forecast a trading range from $10.42 to $15.71, with a likely average price of $13.26. Investors could expect a potential return of -13.56%.
May 2026
Our predictive algorithms indicate Contineum Therapeutics, Inc. Class A Common Stock stock may see a shift in May 2026. The expected range spans $10.46–$14.52, with an average target of $12.55. This represents a cautious outlook and a possible loss of -18.19%.
June 2026
Analyzing established trends, Contineum Therapeutics, Inc. Class A Common Stock looks set to move in June 2026. Projections place the stock between $10.23 and $15.83, averaging around $12.79. This suggests a -16.62% loss from current levels.
July 2026
Market indicators suggest Contineum Therapeutics, Inc. Class A Common Stock could experience notable changes during July 2026. Prices could fluctuate within $11.25 to $16.24, with a midpoint forecast of $13.93. The stock might deliver a -9.19% loss.
August 2026
Forecasting for August 2026, models estimate that Contineum Therapeutics, Inc. Class A Common Stock may undergo key fluctuations. If trends hold, the stock might trade between $9.73 and $14.46, averaging $12.28. This signals a cautious trajectory with potential returns around -19.95%.
September 2026
According to our latest forecast models, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is positioned to show a strong performance in September 2026. The price is predicted to move between $8.22 and $13.81, settling at an average of $11.07. This could translate to a -27.84% loss.
October 2026
Based on current market signals, Contineum Therapeutics, Inc. Class A Common Stock is projected to trend october 2026. We forecast a trading range from $8.03 to $15.43, with a likely average price of $10.52. Investors could expect a potential return of -31.42%.
November 2026
Our predictive algorithms indicate Contineum Therapeutics, Inc. Class A Common Stock stock may see a shift in November 2026. The expected range spans $8.00–$15.24, with an average target of $11.09. This represents a cautious outlook and a possible loss of -27.71%.
December 2026
Analyzing established trends, Contineum Therapeutics, Inc. Class A Common Stock looks set to move in December 2026. Projections place the stock between $8.54 and $14.05, averaging around $11.69. This suggests a -23.79% loss from current levels.
January 2027
Market indicators suggest Contineum Therapeutics, Inc. Class A Common Stock could experience notable changes during January 2027. Prices could fluctuate within $7.63 to $12.65, with a midpoint forecast of $10.11. The stock might deliver a -34.09% loss.
February 2027
Forecasting for February 2027, models estimate that Contineum Therapeutics, Inc. Class A Common Stock may undergo key fluctuations. If trends hold, the stock might trade between $6.21 and $11.72, averaging $8.95. This signals a cautious trajectory with potential returns around -41.66%.
March 2027
According to our latest forecast models, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is positioned to show a strong performance in March 2027. The price is predicted to move between $6.73 and $10.38, settling at an average of $8.49. This could translate to a -44.65% loss.
CTNM's history of dividends and stock splits also plays a role in long-term investor confidence.